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Background: Our purpose was to report acute gastrointestinal (GI) and genitourinary (GU) toxicity rates for prostate
cancer patients undergoing image-guided intensity modulated radiation therapy (IG-IMRT) with a daily endorectal
water-filled balloon (ERBH2O), and assess associations with planning parameters and pretreatment clinical
characteristics.
Methods: The first 100 patients undergoing prostate and proximal seminal vesicle IG-IMRT with indexed-lumen
100 cc ERBH2O to 79.2 Gy in 1.8 Gy fractions at our institution from 12/2008- 12/2010 were assessed. Pretreatment
characteristics, organ-at-risk dose volume histograms, and maximum GU and GI toxicities (CTCAE 3.0) were
evaluated. Logistic regression models evaluated univariate association between toxicities and dosimetric
parameters, and uni- and multivariate association between toxicities and pretreatment characteristics.
Results: Mean age was 68 (range 51–88). Thirty-two, 49, and 19 patients were low, intermediate, and high-risk,
respectively; 40 received concurrent androgen deprivation. No grade 3 or greater toxicities were recorded.
Maximum GI toxicity was grade 0, 1, and 2 in 69%, 23%, and 8%, respectively. Infield (defined as 1 cm above/below
the CTV) rectal mean/median doses, D75, V30, and V40 and hemorrhoid history were associated with grade 2 GI
toxicity (Ps < 0.05). Maximum acute GU toxicity was grade 0, 1, and 2 for 17%, 41%, and 42% of patients,
respectively. Infield bladder V20 (P = 0.03) and pretreatment International Prostate Symptom Scale (IPSS) (P = 0.003)
were associated with grade 2 GU toxicity.
Conclusion: Prostate IG-IMRT using a daily ERBH2O shows low rates of acute GI toxicity compared to previous
reports of air-filled ERB IMRT when using stringent infield rectum constraints and comparable GU toxicities.
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Dose-escalated radiotherapy (RT) as radical treatment
for clinically localized prostate cancer is well-established.
Increasing dose is limited by surrounding normal tis-
sue toxicity, and improved tumor control may come at
the expense of increased toxicity, particularly rectal.
Modern RTechniques including three-dimensional con-
formal (3DCRT), intensity modulated (IMRT), proton
therapy, and daily image guidance (IG) have allowed
for more conformal prostate dose distributions with
improved normal tissue sparing. Additionally, a daily
endorectal balloon (ERB) has been implemented for 1)
prostate immobilization to reduce planning target vol-
ume (PTV) margins [1], [2] and 2) rectal wall sparing
[3], [4].
An air-filled endorectal balloon (ERBair) has been used
in photon therapy for the potential anterior rectal wall
(ARW) surface-sparing effect. Dose perturbation near
the air-tissue interface occurs due to electronic disequi-
librium, leading to lower doses in tissues adjacent to the
air cavity. Monte Carlo (MC) calculations of parallel-
opposed photon beams have shown dose reductions up
to 21%, 15%, and 11%, at the air-rectum interface and 1
and 2 mm depths respectively [5], [6], while a 15% dose
reduction at the air-tissue interface was observed using
multiple-beam IMRT [7]. Despite these apparent advan-
tages, this technique also poses a dosimetric challenge,
because the air introduces significant heterogeneity,
Since almost three-quarters of prostate cancer foci are
present in the peripheral zone [8] in close rectal prox-
imity this has led to concern of potential target under-
dosing. When comparing the Eclipse treatment planning
system to MC simulation using a four-field box tech-
nique and no heterogeneity corrections, Song, et al.
found that the treatment planning system predicted
higher mean doses, and they concluded that a potential
underdosage of 3.4% mean dose for the posterior beam
near the peripheral zone of the prostate was quantified
[9]. Although improvement in dose calculation in het-
erogeneous media was made within the Eclipse TPS
when transitioning from the single pencil beam algo-
rithm (SPB) to the analytical anisotropic algorithm, fur-
ther improvement may be still necessary especially for
dose calculated in the heterogeneous interface area [10].
A daily water-filled endorectal balloon (ERBH2O) has
been routinely employed in proton therapy for dose dis-
tribution optimization [11]. Use of an ERBH2O during
IMRT, rather than air-filled balloon, reduces dosimetric
concern of this dose heterogeneity and potential dimin-
ished target coverage posteriorly. In order to maintain
the favorable rectal toxicity profile, stringent rectal plan-
ning constraints were applied. This study analyzes our
preliminary institutional experience using this approach,
reporting the rates of acute genitourinary (GU) andgastrointestinal (GI) toxicity and assessing for toxicity
associations with dose-volume histogram (DVH) para-
meters as well as patient characteristics. This is the first
report to our knowledge on reporting the acute toxicity
of IG-IMRT using an ERBH2O.
Methods and materials
We retrospectively analyzed the first 100 patients under-
going prostate/proximal seminal vesicle IG-IMRT to
79.2 Gy in 1.8 Gy fractions at our institution between
12/2008 – 12/2010.
Clinical evaluation
Patients had histologically-confirmed, clinically localized
prostate adenocarcinoma evaluated by complete history,
physical examination including digital rectal examin-
ation, bone scintigraphy, and computed tomography
(CT) of the abdomen and pelvis and/or pelvic magnetic
resonance imaging (MRI) ± endorectal coil. Pelvic lymph
nodes were not included in the irradiated target volume.
Concurrent androgen deprivation therapy (ADT), con-
sisting of LHRH analog administration prior to RT initi-
ation, was at the physician’s discretion and offered
primarily to patients with adverse risk features (PSA
>10, cT3a/T3b, and/or Gleason ≥7).
Radiotherapy planning and delivery
Prior to RT, three electromagnetic transponders (Calyp-
soW, Calypso Medical Technologies, Inc, Seattle, WA) or
static fiducial markers (Visicoil™, IBA Dosimetry, Bartlett,
TN) were implanted into the prostate (right base, left
base, and apex) under transrectal ultrasound guidance.
Planning CT was performed at minimum 4 days after im-
plantation on a CT simulator (Siemens USA, New York,
NY). Pre-CT bowel and bladder preparation included
dietary guidelines, regular use of anti-gas tablets, two
self-administered enemas to ensure an empty rectum,
and at least 500 mL of water 20 to 30 minutes prior to
simulation to achieve a full bladder. (Daily enemas were
not required during treatment, however, instructions to
arrive with an empty rectum and full bladder were rein-
forced). Patients were immobilized supine with Knee-
Lok and Foot-Lok cushions (CIVCO, Orange City, IA),
and an indexed lumen, 9 cm ERB (RadiaDyne, LLC,
Houston, TX) was inserted into the rectum and filled
with 100 mL of water. A 1.5-mm slice scan was acquired
at prostate level and isocenter placed in the geometric
center of the markers. The prostate and proximal two-
thirds of the seminal vesicles were outlined by the phys-
ician and identified as the clinical target volume (CTV).
The PTV was generously defined as a 1-cm elliptical ex-
pansion of the CTV in all directions, except 0.6 cm pos-
teriorly. Minimum CTV and PTV coverage was D98
>98% and D95 >95%, respectively. Organs at risk (OARs)
Table 1 Characteristics for the study sample
N 100





Other, Unknown, Hispanic 9























Abbreviations: N= number of patients; SD= standard deviation;
IPSS = International Prostate Symptom Score; BAS = Bowel Assessment Score;
PSA =prostate specific antigen; ADT = androgen deprivation therapy;
GU=genitourinary; PMH=past medical history; HTN =hypertension;
DM=diabetes mellitus.
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base to dome, 2) bladder wall: defined as a 3 mm internal
rind of the bladder surface), 3) rectum: from anus (at is-
chial tuberosity level) to rectosigmoid flexure, and 4) an-
terior rectal wall (ARW): defined as 3 mm rind of the
anterior rectal circumference. “Infield” OARs, defined as
1 cm above and below CTV, were also created for each
structure. Predefined institutional volumetric target dose
constraints included: bladder V65 < 20%, V50 < 45%, and
V45 < 50% and infield rectum V60 < 20%, V45 < 40%, and
V40 < 50%. When necessary, acceptable deviations were
consistent with dose level 3 of RTOG 9406 and consid-
ered ‘minor’ if within 5% of institutional goals. OAR
DVHs were reviewed. IMRT plans were generated using
7–9 coplanar fields (at least 4 of which were posterior
oblique fields traveling through the rectum) with 6 and/
or 15 MV photon beams. Patients were treated with Var-
ian linear accelerators (Varian 2300IX; Varian Medical
Systems, Palo Alto, CA). Setup accuracy was verified for
patients with daily kV-kV portal images to ensure pros-
tate fiducial marker alignment, or in the case of patients
with Calypso beacons, transponder CT coordinates and
isocenter information were imported from Eclipse (Var-
ian Medical Systems), and after appropriate patient setup
adjustments, the system was used in continuous tracking
mode throughout treatment delivery.
Clinical assessment
Patients were monitored weekly during treatment and
seen within 1–3 months after RT completion. At each
visit, a history was obtained with emphasis on
treatment-related morbidity. Toxicities were scored
according to The Common Terminology Criteria for
Adverse Events version 3.0 [12] and International Pros-
tatic Symptom Scale (IPSS) [13]. Maximum grade tox-
icity rates were compared.
Statistical analysis
Baseline patient characteristics – age, race/ethnicity,
PSA, clinical tumor stage, Gleason score, risk group,
concurrent ADT use, type of prostate fiducial marker,
prostate volume, medical co-morbidity (hypertension
(HTN), hyperlipidemia, or diabetes mellitus (DM)), pre-
RT urinary signs/symptoms, and pretreatment IPSS –
were reported.
Using logistic regression analysis, statistical associations
were investigated between grade ≥2 GU toxicity and (1)
bladder dosimetric parameters and (2) pretreatment
demographics, including age, PSA, pathologic tumor
stage, Gleason score, concurrent ADT, HTN, hyperlipid-
emia, DM, IPSS, and pre-RT GU past medical history
(PMH) defined as an antecedent history of significant
urinary sign or symptoms, including benign prostatic
hyperplasia, prior trans-urethral resection of the prostate,bladder outlet obstruction, and/or lower urinary tract
symptoms. Similarly, associations were investigated separ-
ately between grade≥ 2 and (1) rectal dosimetric para-
meters and (2) the aforementioned pretreatment
demographics, excluding IPSS and pre-RT GU PMH. Pre-
treatment demographics with significant univariate tox-
icity associations (p values of <0.10) were considered in a
multivariate logistic regression model. Given relatively low
numbers of Grade ≥2 toxicities, to preserve robust estima-
tion, no more than two variables were included in the final
model. Although multiple statistical tests were performed,
due to the preliminary nature of the analysis, a p value of
<0.05 was considered statistically significant. Statistical
analyses were conducted using Stata version 11 software
(StataCorp, College Station, TX).
Table 2 Acute Maximum GU and GI Toxicities with IMRT
using a water-filled endorectal balloon
GU GI






Abbreviations: GU=genitourinary; GI = gastrointestinal; IMRT = intensity
modulated radiation therapy.
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All patients tolerated the ERB throughout the entire
treatment course. Pretreatment demographics are listed
in Table 1. The majority of patients had clinical stage
T1c, Gleason 6 or 7 disease, median PSA 7.6, mean age
68, mean prostatic volume 45 cc, and mean IPSS 8.
GI toxicity
Toxicities are summarized in Table 2; no grade ≥3 toxi-
cities were observed. Maximum GI toxicity was grade 0,
1, and 2 in 69%, 23%, and 8%, respectively. One patient
reported grade 2 enteritis using oral anti-diarrheal medi-
cation. Seven patients reported grade 2 rectal proctitis
or bleeding, 3 (43%) of which reported a history of
hemorrhoids prior to treatment initiation, while only 2/
14 (14%) with grade 1 and 6/79 (7.6%) with grade 0
lower GI tract toxicity reported similar history. OnTable 3 Rectum RTOG, Anterior Rectal Wall RTOG, Rectum Pa
Univariate Associations with Grade≥2 GI Toxicities
Grade≥ 2 Combined GI/rectal Rectum Infield Rec
Mean± SD P value Mean± SD
Volume (cm3) 167.1 ± 31.4 0.57 131.5 ± 25.3
Dmin (Gy) 4.2 ± 3.7 0.64 12.3 ± 4.6
Dmax (Gy) 81.8 ± 1.7 0.44 81.8 ± 1.7
Dmean (Gy) 36.0 ± 5.1 0.28 42.1 ± 4.1
Dmedian (Gy) 31.7 ± 5.9 0.09 35.9 ± 5.2
V10 (%) 87.4 ± 10.4 0.99 99.3 ± 2.1
V20 (%) 77.1 ± 14.5 0.46 91.5 ± 11.6
V30 (%) 57.1 ± 14.5 0.08 69.2 ± 15.3
V40 (%) 35.4 ± 7.6 0.13 43.4 ± 8.4
V50 (%) 24.2 ± 4.5 0.53 29.9 ± 4.8
V60 (%) 17.0 ± 3.0 0.85 21.3 ± 3.3
V65 (%) 14.0 ± 2.5 0.87 17.5 ± 2.9
V70 (%) 10.9 ± 2.2 0.86 13.7 ± 2.7
V75 (%) 7.2 ± 2.2 0.74 9.1 ± 2.7
V79.2 (%) 2.4 ± 2.1 0.49 3.0 ± 2.5
Abbreviations: DVH=dose volume histogram; Dmin =minimum dose; Dmedian =medi
V65, V70, V75, V79.2 = volume receiving 10 Gy, 20 Gy, 30 Gy, 40 Gy, 50 Gy, 60 Gy, 65 G
Note: The results are presented as mean± standard deviation. The results listed as N
parameter.univariate analysis, only hemorrhoid history was signifi-
cantly associated (P = 0.025) with GI grade 2 toxicity.
GU toxicity
Maximum GU toxicity was grade 2 (42%), grade 1 (41%),
and grade 0 (17%). Grade 2 GU toxicity consisted of fre-
quency (24%), urgency (13%), dysuria (6%), incontinence
(4%), obstruction (2%), and retention (2%) with some
patients reporting multiple grade 2 toxicities. The major-
ity of acute grade 2 GU events involved initiation or in-
crease in alpha-blocker or less frequently, anti-spasmodic.
The mean pretreatment IPSS was 8 ± 7 (0–34), and the
mean subjective IPSS score was 2 ± 1 (0–5). The mean
post-treatment IPSS was 10 ± 6 (1–24), and the mean
subjective IPSS score was 2 ± 1 (0–5). The mean absolute
change in pre- and post-treatment IPSS was 2±5 (−7 - 16).
The mean percentage change in pre- and post-treatment
IPSS was 6%± 15% (−20% - 46%). Thus, the IPSS in-
creased on average 2 points from pre- to immediate
post-treatment recording, while the subjective IPSS score
on average was unchanged, confirming the tolerability
and mild bother of such treatment.
Thirty-four percent of patients had an antecedent GU
PMH, however this was not associated with the occur-
rence of grade ≥2 GU toxicity. On univariate analysis,
concurrent ADT (P = 0.08) and IPSS values pre-RT
(P = 0.003), post-RT (P = 0.018), absolute increase
(P = 0.013), and percentage increase (P = 0.013) – were
all associated with acute grade ≥2 GU toxicity. Only pre-rtial, Anterior Rectal Wall Partial DVH Analysis and
tum Anterior Rectal Wall Infield Anterior Rectal Wall
P value Mean± SD P value Mean± SD P value
0.59 26.9 ± 5.7 0.63 20.7 ± 4.6 0.54
0.08 5.8 ± 5.8 0.87 20.6 ± 7.3 0.17
0.44 81.8 ± 1.7 0.40 81.8 ± 1.7 0.40
0.04 54.2 ± 7.1 0.82 64.6 ± 3.1 0.48
0.03 60.5 ± 8.7 0.91 70.9 ± 4.4 0.73
0.64 88.6 ± 10.1 0.81 99.9 ± 0.3 NA
0.21 84.7 ±11.2 0.92 99.6 ± 1.3 0.39
0.02 80.8 ± 11.5 0.79 97.6 ± 3.4 0.30
0.046 72.8 ± 11.5 0.76 89.6 ± 6.0 0.35
0.24 62.1 ± 10.4 0.95 77.5 ± 7.2 0.90
0.48 51.8 ± 9.2 0.91 65.6 ± 7.2 0.96
0.51 46.6 ± 8.5 0.98 59.3 ± 7.1 0.81
0.54 40.8 ± 8.1 0.95 52.2 ± 7.5 0.71
0.55 32.2 ± 8.4 0.75 41.4 ± 9.4 0.58
0.37 12.7 ± 9.8 0.42 16.4 ± 12.2 0.31
an dose; Dmean =mean dose; Dmax =maximum dose; V10, V20, V30, V40, V50, V60,
y, 70 Gy, 75 Gy, 79.2 Gy, respectively.
A were not estimated due to the limited number of variations in the tested
Table 4 Bladder, Bladder Wall, Proximal Bladder, and Proximal Bladder Wall DVH Analysis and Univariate Associations
with Grade≥2 GU Toxicities
Bladder In-field Bladder Bladder Wall In-field Bladder Wall
Mean± SD P value Mean± SD P value Mean± SD P value Mean± SD P value
Volume (cm3) 246± 167 0.31 101.5 ± 42.9 0.34 55.2 ± 24.6 0.44 25.9 ± 8.1 0.65
Dmin (Gy) 3.6 ± 4.7 0.92 13.0 ± 5.9 0.55 3.6 ± 4.7 0.94 12.5 ± 6.6 0.21
Dmax (Gy) 82.5 ± 1.6 0.26 82.5 ± 1.6 0.26 82.4 ± 1.6 0.24 82.4 ± 1.6 0.24
Dmean (Gy) 31.0 ± 11.2 0.64 50.4 ± 5.8 0.16 33.2 ± 10.6 0.72 54.9 ± 5.7 0.23
Dmedian (Gy) 23.1 ± 15.2 0.62 48.6 ± 8.1 0.16 23.4 ± 16.2 0.60 56.0 ± 9.9 0.20
V10 (%) 66.6 ± 25.1 0.66 99.2 ± 3.2 0.11 64.6 ± 22.8 0.61 99.0 ± 2.9 0.14
V20 (%) 57.1 ± 24.1 0.55 94.6 ± 7.6 0.03 56.2 ± 20.9 0.66 94.5 ± 6.5 0.06
V30 (%) 46.4 ± 20.4 0.65 81.3 ± 11.1 0.20 47.1 ± 17.5 0.84 82.6 ± 9.5 0.37
V40 (%) 35.4 ± 15.0 0.65 64.6 ± 11.9 0.48 38.7 ± 13.6 0.86 69.7 ± 10.5 0.57
V50 (%) 25.4 ± 10.1 0.40 48.0 ± 11.4 0.27 30.5 ± 10.4 0.61 56.1 ± 10.9 0.30
V60 (%) 17.9 ± 7.3 0.46 34.6 ± 10.0 0.32 24.2 ± 8.5 0.63 45.4 ± 10.6 0.34
V65 (%) 15.1 ± 6.3 0.41 29.4 ± 9.2 0.26 21.9 ± 7.8 0.59 41.3 ± 10.1 0.30
V70 (%) 12.4 ± 5.4 0.38 24.6 ± 8.3 0.23 19.7 ± 7.1 0.56 37.5 ± 9.6 0.29
V75 (%) 9.5 ± 4.4 0.32 18.9 ± 7.4 0.22 16.9 ± 6.4 0.45 32.6 ± 9.3 0.24
V79.2 (%) 4.7 ± 3.0 0.45 9.9 ± 6.5 0.48 10.2 ± 5.3 0.52 20.6 ± 10.4 0.45
Abbreviations: DVH=dose volume histogram; Dmin =minimum dose; Dmedian =median dose; Dmean =mean dose; Dmax =maximum dose; V10, V20, V30, V40, V50, V60,
V65, V70, V75, V79.2 = volume receiving 10 Gy, 20 Gy, 30 Gy, 40 Gy, 50 Gy, 60 Gy, 65 Gy, 70 Gy, 75 Gy, 79.2 Gy, respectively.
Note: The results are presented as mean± standard deviation.
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tivariate analysis.
Dosimetry and dosimetric-toxicity associations
IMRT plans provided excellent coverage, with all plans
achieving target coverage goals. No hot spots were
located within the OAR or OAR-target volume inter-
faces. Six patients did not have all bladder constraints
met, 4 of whom had single deviations <5%. Twelve
patients did not have all infield rectum constraints met,
9 of whom had a single deviation <2%. Figure 1 shows
the mean DVHs for the reported OARs. Tables 3 and 4
show the mean± standard deviation of the DVH para-
meters assessed for the reported OARs, as well as the
univariate association with grade ≥2 GI and GU toxicity,
respectively. On logistic regression analyses, only infieldTable 5 Comparative Rates of Acute Maximum RTOG
Grade GI Toxicity for Prostate IMRT with no Endorectal




Toxicity Grade % % %
0 63 68 69
1 23 14 23
2 13 18 8
3 0 0 0
4 0 0 0
Abbreviations: GU=genitourinary; GI = gastrointestinal; IMRT = intensity
modulated radiation therapy; ERB = endorectal balloon; H2O – water.bladder V20 was associated with the occurrence of grade
≥2 toxicity (P = 0.033), while the infield bladder wall V20
was marginally associated (P = 0.061). Grade 2 GI tox-
icity was associated with infield rectal mean/median
doses, D75, V30, and V40 (Ps < 0.05), and did not associate
with rectum, ARW and infield ARW parameters.
Discussion
This study is the first to our knowledge to report the
acute toxicity of prostate cancer patients treated with
IG-IMRT using an ERBH2O. Grade ≥2 GI and GU tox-
icity rates of 8% and 42%, respectively, compare favor-
ably with patients treated with IMRT using an ERBair for
which there is only single institution data reporting rates
of acute GI and GU toxicity of 18% and 35%, respect-
ively, in 396 prostate cancer patients treated from 1997–
2001 with mean dose 77 Gy (specifically 70 Gy in 2 Gy
daily fractions prescribed to the 85% isodose line) IMRT
using 100 cc ERBair [14]. The toxicity rates for our co-
hort are also comparable to the more extensively re-
ported acute GI and GU toxicity rates for non-ERB
prostate IMRT including from our own institution at
13% and 50%, respectively [15]. These comparative rates
for acute GI toxicity are summarized in Table 5. While
PTV margins were the same in our ERB and non-ERB
cohorts, in these initial 100 patients treated with a
water-filled balloon and IG-IMRT, more stringent con-
straints were implemented for the bladder and rectum
in this cohort and may explain the more favorable tox-
icity profile. Following our intrafraction prostate motion
Deville et al. Radiation Oncology 2012, 7:76 Page 6 of 7
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margins to 5 mm, except 4 mm posteriorly.
Only hemorrhoid history was significantly associated
on univariate analysis with grade 2 GI toxicity. Pre-
existing hemorrhoid history has varied in significance in
prior ERB studies. In one study, patients with pre-
existing hemorrhoids did not have an increased risk of
complaints [16], while in another it was considered a
contraindication for the use of ERBs, as application led
to grade 3 anal irritation in a patient with hemorrhoids
[17]. In the Baylor report, patients with pre-existing ano-
rectal disease had a higher risk of developing acute ano-
rectal toxicity; 43% with pre-existing history of anorectal
disease vs. 16% without reported acute grade 2 GI tox-
icity [14].
DVH-toxicity analysis revealed no association for the
rectum when anatomically contoured per RTOG guide-
lines. Contrastingly, infield rectum mean/median doses,
D75, V30, and V40 were associated with combined upper
and lower GI grade 2 toxicity (Ps <0.05). In their initial
acute toxicity report of the first 100 patients treated with
IMRT utilizing an ERBair, the Baylor group found no re-
lationship between acute rectal toxicity and rectal mean
dose or rectal V65, V70, and V75 [18]. In that study, rec-
tal delineation was not specified, and intermediate dose
level parameters were not assessed. Dosimetric data
assessing specifically acute GI toxicity associations and
rectal parameters are also limited in the non-ERB IMRT
setting. As the QUANTEC report recently summarized,
most of the mature published clinical data on dose-
related rectal toxicity come from non-ERB 3DCRT and
focus on either cumulative or late toxicity, concluding
that the high-dose regions are most predictive [19]. Still,
particularly when considering ERB use, our findings are
consistent with their conclusion that reduced rectal
volumes exposed to intermediate dose ranges by IMRT
may become more important in assessing associations
with toxicity.
The GU toxicity profile of prostate IMRT using an
ERBH2O is not expected to vary from ERBair and non-
ERB prostate IMRT, as the dose distribution to the blad-
der is not significantly altered with ERB use. As noted
above, GU toxicity rates remain consistent overall. On
univariate and multivariate analysis, pre-treatment IPSS
remained significant, confirming its continued relevance
in predicting likelihood of acute grade ≥2 GU toxicity
with ERB use. There were no associations with bladder
or bladder wall DVH parameters. Similarly, the Baylor
group found no relationship between acute GU toxicity
and bladder DVH parameters [14], corroborating reports
that bladder DVH parameters generally do not consist-
ently correlate with acute or late GU toxicities. Still, in
the follow-up setting, there have been reports noting
similar volumetric associations with late GU toxicity,demonstrating that the bladder wall V30 > 30 cc and
V82 > 7 cc [20] and the fractional bladder volume receiv-
ing more than 14 to 27 Gy [21] were clinically useful
predictors. In this analysis, infield bladder V20 was asso-
ciated with the occurrence of grade ≥2 toxicity, while
the infield bladder wall V20 was marginally associated,
suggesting that further investigation of infield bladder
DVH parameters may be relevant in the analysis of acute
toxicity.
This is preliminary report is limited by its retrospect-
ive, nonrandomized nature. We await increased numbers
and follow-up for further analysis including biochemical
control, correlates with acute and eventually late toxicity,
and comparison to non-ERB patients. PTV margins have
subsequently reduced to 5 mm except 4 mm posteriorly
based on our motion analysis papers, which may allow
for further reductions in volumes of bladder and rectum
irradiated potentially affecting the toxicity profile. Add-
itional limitations are the tools used for toxicity assess-
ment: CTCAE grading and IPSS. More comprehensive
systems, such as the complete Expanded Prostate cancer
Index Composite (EPIC) [22] - since implemented in
our clinic - may assess subtler, but still clinically relevant
morbidity, particularly assessing the bowel function and
bother domains. Finally, as noted in the statistical ana-
lysis section, due to the preliminary and exploratory na-
ture of the dosimetry-toxicity association analyses,
although multiple statistical tests were performed, a p
value of <0.05 was still considered statistically signifi-
cant, however, it is therefore possible that p-values < 0.05
were based on chance. Despite these limitations, we felt
that a preliminary report was merited, as the acute tox-
icity profile of IG-IMRT using an ERBH2O has not yet
been reported in the literature.Conclusion
Prostate IG-IMRT using a daily ERBH2O shows low rates
of acute GI toxicity compared to previous reports of
ERBair IMRT when using strict infield rectum con-
straints and comparable GU toxicities. Comprehensive
dosimetric analysis of this cohort revealed that inter-
mediate dose-level infield rectal (mean/median doses,
D75, V30, and V40) and low dose in-field bladder (V20)
parameters were associated with acute toxicity, as well
as, hemorrhoid history and pretreatment IPSS.
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